Navigation Links
VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
Date:4/16/2009

First Selective TLR8 Agonist to Advance for Treatment of Allergy

SAN DIEGO, April 16 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) agonists for the treatment of cancer, respiratory and inflammatory diseases, announced today that it has initiated a Phase I clinical trial of VTX-1463, a selective intranasal TLR8 agonist for the treatment of allergic rhinitis. The objectives of this trial will be to assess safety, tolerability and pharmacokinetics of single and multiple ascending doses of VTX-1463 in approximately 30 healthy volunteers. The trial is being conducted in the Netherlands.

"We are pleased to advance VTX-1463 into the clinic," said Dr. Robert Hershberg, Executive Vice President and Chief Medical Officer at VentiRx. "This is another milestone for our TLR8 effort as this is the second clinical program initiated in the last six months." VTX-2337 began Phase I clinical trials in cancer patients in November 2008.

VTX-1463 is a small molecule TLR8 agonist that is being developed as a stand-alone agent for the treatment of allergic rhinitis. In preclinical animal studies, this compound has been shown experimentally to dramatically reduce allergic responses without requiring the concomitant administration of allergen. As such, it represents a potential prophylactic and/or therapeutic solution for allergic diseases, regardless of the antigen responsible for the allergic response. The first clinical trial will investigate the safety and pharmacology of multiple doses of VTX-1463 in healthy volunteers and will help define the appropriate dose(s) for a proof of concept clinical study in allergic patients later this year.

"VTX-1463 is the first selective TLR8 compound to reach the clinic for allergy," said Michael Kamdar, Executive Vice President and Chief Business Officer at VentiRx. "Aller
'/>"/>

SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
2. Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy
3. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
4. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
5. Strativa Pharmaceuticals Provides Product Pipeline Update
6. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
7. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
8. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
9. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
10. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
11. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... directors of Eli Lilly and Company (NYSE: ... quarter of 2010 of $0.49 a share on outstanding ... March 10, 2010 to shareholders of record at the ... ,, Lilly, a leading innovation-driven corporation, is developing a ... research from its own worldwide laboratories and from collaborations ...
(Date:12/14/2009)... -- Cardinal Health today announced that executives of the ... Goldman Sachs CEO Unplugged Conference on ... Conference Center in New York. 28th Annual ... Noon EST at the Westin St. Francis Hotel in ... will discuss Cardinal Health,s diverse products and services, company ...
(Date:12/14/2009)... Conn., Dec. 14 Zargis Medical Corp., ... SPDE ) and a spin-off from Siemens Corporate ... that it has begun selling its award-winning Zargis ... ,, Cardioscan and its accompanying Bluetooth®-enabled electronic stethoscope ... "2009 Innovation of the Year." ...
Breaking Medicine Technology:Cardinal Health Executives to Speak at Two Investor Events in January 2Zargis Cardioscan 'The Intelligent Stethoscope' Now Available on Amazon.com 2Sheller P C Law Firm Instrumental in Pfizers 242 3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 56021 1Sheller P C Law Firm Instrumental in Pfizers 242 3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 56021 2Sheller P C Law Firm Instrumental in Pfizers 242 3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 56021 3Sheller P C Law Firm Instrumental in Pfizers 242 3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 56021 4Sheller P C Law Firm Instrumental in Pfizers 242 3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 56021 5eDiets com Selects Karlin+Pimsler to Lead Creative Turnaround 56017 1eDiets com Selects Karlin+Pimsler to Lead Creative Turnaround 56017 2MDS Announces Voting Support Agreements 56014 1MDS Announces Voting Support Agreements 56014 2MDS Announces Voting Support Agreements 56014 3
(Date:12/14/2009)... Pasierb, President ,, NEW YORK, Dec. 14 ... the Future study (MTF) -- the largest survey on ... 12th graders -- underscores that teens, intentional abuse of ... a cause for concern, with an alarming number of ... relatives. ,, Teen Abuse of Medication ...
(Date:12/14/2009)... SANTA ANA, Calif., Dec. 14 Grubb & Ellis ... directors has authorized a daily distribution to stockholders of record ... the period commencing on Jan. 1, 2010 and ending on ... on 365 days in the calendar year and will be ... a purchase price of $10.00 per share. These distributions ...
(Date:12/14/2009)... 14 On December 9, 2009, the United ... government,s position that private insurance companies are "plans" and ... Although other federal courts have held that contracts issued ... under Title 18 Section 1347, US vs. Frost ... has been held to be a "plan," because, as ...
(Date:12/14/2009)... had been treated, hadn,t spread, study finds , , MONDAY, ... the risk of death in male colon cancer survivors, ... 1986, included 668 men who,d been treated for stage ... had not spread (nonmetastatic cancer). Every two years, the ... new cancer and disease diagnoses, as well as their ...
(Date:12/14/2009)... is small and shouldn,t worry most users, researcher says ... who take antidepressants may have a small but statistically ... women not on the medications, a new study finds. ... significance," stressed Dr. Jordan W. Smoller, an associate professor ... of a report in the Dec. 14 issue of ...
Breaking Medicine News(10 mins):Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 3Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 2Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 3Health News:Insurance Now Subject to Federal Jurisdiction 2Health News:Physical Activity May Prolong Survival After Colon Cancer 2Health News:Antidepressants May Raise Women's Stroke Risk 2Health News:Antidepressants May Raise Women's Stroke Risk 3
... "Executive of the Year." , ... Birmingham, AL (PRWEB) ... International, and its CEO Jeffrey Tolbert took home two awards in ... Business Journal., , ,AirMed International was announced as the winner in ...
... follows nearly two-year ... delay in releasing data, WASHINGTON, Aug. ... Control and Prevention (CDC) increase,the estimate of new HIV infections in ... does not necessarily indicate an,ongoing increase in the annual estimated infection ...
... of lopinavir/ritonavir, study says , , FRIDAY, ... tazanavir/ritonavir (A/R) is as effective as twice-daily treatment ... starting antiretroviral treatment for the first time, a ... the researchers recommended once-daily A/R as a first-line ...
... study regarding Cognitive Behavioral Therapy as a treatment for Body Dysmorphic Disorder. ... into a crisis. BDD is similar to other disorders that respond ... thoughts on the study. , ... New York, NY (PRWEB) August 2, ...
... KNSY ) today announced that it will release ... ended June 30, 2008 at 7:00 A.M.,Eastern Time on ... CEO, will be hosting a teleconference,discussing the earnings results ... To participate in the teleconference call, dial 612-332-0345. ...
... the most aggressive types of brain tumor, have an ... a group of proteins known as receptor tyrosine kinases ... these RTK inhibitors have met with limited clinical success ... such treatment and most subsequently relapse after only a ...
Other Medicine News:Health News:Air Ambulance Company AirMed International Wins Multiple "Best in Business" Awards from Birmingham Business Journal 2Health News:New HIV Infection Figures from CDC Underscore Need for National AIDS Strategy for the U.S. 2Health News:Once-Daily Combo Works for New HIV Patients 2Health News:Has Hollywood's Diet Obsession Forced the US Government to Take Action? 2Health News:Has Hollywood's Diet Obsession Forced the US Government to Take Action? 3Health News:Kensey Nash Corporation Announces its Fourth Quarter and Fiscal Year End 2008 Earnings Release Date and Teleconference 2
... lumen tubes for ... ,Each SHER-I-BRONCH ... packaged with pre-loaded ... suction catheters and ...
Used for endobronchial blockade of the left or right lung for procedures which require one-lung ventilation. Supplied sterile in peel-open packages. Intended for one-time use....
... allows quick and safe access ... of acute respiratory distress with ... consists of a pre-assembled emergency ... syringe attached to a padded ...
Used for emergency airway access when endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: